DZ2518A1 - Inhibiteurs de farnésyl - transférase en association avec des inhibiteurs de HMG-Coa-reductase pour le traitement du cancer. - Google Patents

Inhibiteurs de farnésyl - transférase en association avec des inhibiteurs de HMG-Coa-reductase pour le traitement du cancer.

Info

Publication number
DZ2518A1
DZ2518A1 DZ980128A DZ980128A DZ2518A1 DZ 2518 A1 DZ2518 A1 DZ 2518A1 DZ 980128 A DZ980128 A DZ 980128A DZ 980128 A DZ980128 A DZ 980128A DZ 2518 A1 DZ2518 A1 DZ 2518A1
Authority
DZ
Algeria
Prior art keywords
inhibitors
hmg
coa
cancer
treatment
Prior art date
Application number
DZ980128A
Other languages
English (en)
French (fr)
Inventor
Shama Mohammed Kajiji
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DZ2518A1 publication Critical patent/DZ2518A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DZ980128A 1997-06-16 1998-06-15 Inhibiteurs de farnésyl - transférase en association avec des inhibiteurs de HMG-Coa-reductase pour le traitement du cancer. DZ2518A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4963897P 1997-06-16 1997-06-16

Publications (1)

Publication Number Publication Date
DZ2518A1 true DZ2518A1 (fr) 2003-02-01

Family

ID=21960890

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980128A DZ2518A1 (fr) 1997-06-16 1998-06-15 Inhibiteurs de farnésyl - transférase en association avec des inhibiteurs de HMG-Coa-reductase pour le traitement du cancer.

Country Status (37)

Country Link
EP (1) EP0986387B1 (no)
JP (1) JP3713051B2 (no)
KR (1) KR100392573B1 (no)
CN (1) CN1259868A (no)
AP (1) AP9801261A0 (no)
AR (1) AR013090A1 (no)
AT (1) ATE235905T1 (no)
BG (1) BG103946A (no)
BR (1) BR9810616A (no)
CA (1) CA2294399C (no)
CO (1) CO4950607A1 (no)
DE (1) DE69812933T2 (no)
DK (1) DK0986387T3 (no)
DZ (1) DZ2518A1 (no)
EA (1) EA199901043A1 (no)
ES (1) ES2196559T3 (no)
GT (1) GT199800081A (no)
HN (1) HN1998000091A (no)
HR (1) HRP980328B1 (no)
HU (1) HUP0004624A3 (no)
ID (1) ID23014A (no)
IL (1) IL132765A0 (no)
IS (1) IS5259A (no)
MA (1) MA24569A1 (no)
NO (1) NO996206L (no)
NZ (1) NZ500662A (no)
OA (1) OA11231A (no)
PA (1) PA8453601A1 (no)
PE (1) PE82899A1 (no)
PL (1) PL337651A1 (no)
PT (1) PT986387E (no)
SK (1) SK169699A3 (no)
TN (1) TNSN98088A1 (no)
TR (1) TR199903074T2 (no)
UA (1) UA57081C2 (no)
WO (1) WO1998057633A1 (no)
ZA (1) ZA985182B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1077949A2 (en) 1998-05-12 2001-02-28 Warner-Lambert Company Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer
AU6256499A (en) * 1998-09-24 2000-04-10 Merck & Co., Inc. A method of treating cancer
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
CA2432137C (en) 2000-12-19 2010-12-21 Pfizer Products Inc. Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
JP4092203B2 (ja) 2000-12-21 2008-05-28 ニトロメッド，インク． 新規のシクロオキシゲナーゼ２選択的阻害剤としての置換アリール化合物、組成物、および使用方法
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
JP2005200419A (ja) * 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083985A (en) * 1995-08-09 2000-07-04 Banyu Pharmaceutical Co., Ltd. Medicinal composition

Also Published As

Publication number Publication date
AU7445998A (en) 1999-01-04
AU724676B2 (en) 2000-09-28
CO4950607A1 (es) 2000-09-01
JP3713051B2 (ja) 2005-11-02
PL337651A1 (en) 2000-08-28
KR20010013839A (ko) 2001-02-26
DE69812933D1 (de) 2003-05-08
ZA985182B (en) 1999-12-17
EP0986387A1 (en) 2000-03-22
HUP0004624A2 (hu) 2001-10-28
PA8453601A1 (es) 2000-05-24
HRP980328A2 (en) 1999-04-30
HRP980328B1 (en) 2002-06-30
EA199901043A1 (ru) 2000-06-26
CN1259868A (zh) 2000-07-12
MA24569A1 (fr) 1998-12-31
BR9810616A (pt) 2000-09-12
PT986387E (pt) 2003-06-30
DK0986387T3 (da) 2003-07-14
IL132765A0 (en) 2001-03-19
AP9801261A0 (en) 1999-12-11
NO996206D0 (no) 1999-12-15
HUP0004624A3 (en) 2002-11-28
UA57081C2 (uk) 2003-06-16
TNSN98088A1 (fr) 2005-03-15
NO996206L (no) 2000-02-15
ATE235905T1 (de) 2003-04-15
SK169699A3 (en) 2000-06-12
DE69812933T2 (de) 2003-11-06
WO1998057633A1 (en) 1998-12-23
IS5259A (is) 1999-11-19
PE82899A1 (es) 1999-08-26
CA2294399A1 (en) 1998-12-23
CA2294399C (en) 2004-03-16
JP2000513031A (ja) 2000-10-03
HN1998000091A (es) 1999-09-29
NZ500662A (en) 2001-10-26
AR013090A1 (es) 2000-12-13
BG103946A (bg) 2000-07-31
EP0986387B1 (en) 2003-04-02
GT199800081A (es) 1999-12-07
TR199903074T2 (xx) 2000-05-22
ID23014A (id) 1999-12-30
ES2196559T3 (es) 2003-12-16
KR100392573B1 (ko) 2003-07-23
OA11231A (en) 2003-05-26

Similar Documents

Publication Publication Date Title
CY2006007I1 (el) Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας
HK1037981A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis C.
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
DE69624812D1 (de) Verringerung des mehrwegeffekts in gps-empfängern
DZ2518A1 (fr) Inhibiteurs de farnésyl - transférase en association avec des inhibiteurs de HMG-Coa-reductase pour le traitement du cancer.
HK1036279A1 (en) Farnesyl protein transferase inhibitors.
ZA964298B (en) Use of aryl-substituted cyclobutylalkylamines for the treatment of obesity.
IT1285874B1 (it) Metodo per giudicare le proprieta' di ghisa fusa.
ZA964761B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
EP0567275A3 (en) Hydrazones for water treatment of boilers.
IS2253B (is) Notkun á eletriptani til fyrirbyggingar á endurteknu mígreni
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
FR2752924B3 (fr) Clayette pour refrigerateurs
FR2721930B1 (fr) Oligonucleotides pour inhiber le role des isoprenyl proteine transferases
FR2715715B1 (fr) Améliorations introduites dans les circuits de dégazage des radiateurs.
MXPA03002280A (es) Proceso para purificacion de isooctano y/o diisobutileno.
IT248614Y1 (it) Apparecchiatura per l'applicazione in sequenza di coperchietti sulattine o barattoli.
KR960007932U (ko) 생수통
GB9825969D0 (en) Agents useful in the treatment of reproductive disorders
KR960005053U (ko) 생수용기 밀페캡
GB0111564D0 (en) Fluid treatment tank
KR970051801U (ko) 생수통
FR2719884B1 (fr) Robinet d'eau et élément de vanne pour le robinet.
ES1041446Y (es) Dispositivo de iluminacion de bañeras y griferia.